Brivaracetam
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Brivaracetam: From Focal Onset Epilepsy to Visual Epilepsy
One-Sentence Summary
Brivaracetam (BRV) is a third-generation antiseizure medication (ASM) approved internationally for focal onset seizures, acting as a selective, high-affinity ligand for synaptic vesicle protein 2A (SV2A). The TxGNN model predicts it may be effective for Visual Epilepsy (including photosensitive and visually-triggered seizures), with 0 registered clinical trials and 19 publications providing supporting mechanistic and indirect clinical context. Brivaracetam is not currently marketed in Australia, and no ARTG entries exist for this drug.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Focal onset seizures (approved in USA and EU; not registered in Australia) |
| Predicted New Indication | Visual Epilepsy |
| TxGNN Prediction Score | 99.51% |
| Evidence Level | L3 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the current dataset. However, based on extensive published literature, Brivaracetam binds to synaptic vesicle glycoprotein 2A (SV2A) with 15- to 30-fold greater affinity than levetiracetam, its closest comparator, and crosses the blood-brain barrier more rapidly due to its superior lipophilicity. By inhibiting SV2A-mediated synaptic vesicle cycling, BRV suppresses excessive neurotransmitter release and reduces cortical network hyperexcitability — the core mechanism underlying seizure generation and propagation across epilepsy subtypes (PMID 32120063, PMID 38811492).
Visual epilepsy — including photosensitive epilepsy, in which flickering lights or visual patterns trigger synchronised epileptiform discharges in the occipital cortex — shares the same fundamental pathophysiology of cortical hyperexcitability that BRV targets. The Photoparoxysmal Response (PPR) model, the gold-standard human proof-of-concept platform for antiseizure drug evaluation in photosensitive epilepsy, has directly demonstrated BRV’s capacity to eliminate PPR-associated discharges, and with faster onset than levetiracetam (PMID 32949370). This provides strong biologically plausible, if indirect, mechanistic support for the TxGNN prediction.
Focal onset seizures — BRV’s internationally approved indication — and visually-triggered seizures share overlapping cortical excitability pathways, particularly involving the occipital and parieto-occipital networks. BRV’s additional activity at voltage-gated sodium channels (Nav1.2 blockade), beyond its primary SV2A mechanism, may further broaden its antiseizure coverage across multiple cortical networks relevant to visual epilepsy syndromes.
Clinical Trial Evidence
Currently no clinical trials specifically addressing Brivaracetam in visual epilepsy are registered on ClinicalTrials.gov or ICTRP.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31195850 | 2019 | Systematic Review / Meta-analysis | Expert Review of Neurotherapeutics | BRV has 15–30× greater SV2A affinity than levetiracetam; comprehensive review of clinical trial and post-marketing data confirms efficacy and tolerability in focal epilepsy |
| 40568060 | 2025 | Comprehensive Review | Journal of Epilepsy Research | Synthesises clinical trial and real-world evidence; BRV’s rapid BBB penetration and selective SV2A binding contribute to favourable efficacy, tolerability, and approval as both adjunctive and monotherapy |
| 38576178 | 2024 | Phase III RCT | Epilepsia Open | Phase III double-blind, placebo-controlled trial in adult Asian patients with uncontrolled focal-onset seizures; BRV demonstrated significant seizure reduction, safety, and tolerability |
| 38970892 | 2024 | Pooled Analysis | Epilepsy & Behavior | EXPERIENCE pooled analysis of BRV in older (≥65 years) and younger adults; includes real-world Australian patient data; consistent effectiveness and tolerability across age groups |
| 38811492 | 2024 | Narrative Review | Advances in Therapy | Covers BRV preclinical profile and clinical benefits; SV2A affinity and additional Nav channel activity described as basis for broader antiseizure spectrum |
| 39664134 | 2024 | Systematic Review | Cureus | Systematic review of BRV efficacy, safety, and reasons for switching from prior AEDs to BRV in adults and children with epilepsy; switch from LEV to BRV common due to improved tolerability |
| 31937513 | 2020 | Pooled Safety Analysis | Epilepsy & Behavior | In-depth pooled safety analysis of adjunctive BRV for focal seizures; favourable safety profile established across a large patient population |
| 37483441 | 2023 | Systematic Review & Meta-analysis | Frontiers in Neurology | Meta-analysis of BRV safety and efficacy in paediatric epilepsy; positive outcomes and acceptable adverse event profile in children |
| 32120063 | 2020 | Review | Neuropharmacology | Comprehensive review of mechanisms of currently used antiseizure drugs; BRV’s SV2A-mediated mechanism and broader cortical excitability suppression described |
| 26165169 | 2015 | Meta-analysis | Expert Opinion on Pharmacotherapy | Meta-analysis of BRV at different doses vs placebo as adjunctive therapy for partial-onset epilepsy; dose-dependent efficacy and safety established |
Australia Market Information
Brivaracetam is not currently registered on the Australian Register of Therapeutic Goods (ARTG). There are no ARTG entries for this drug as of the data cut-off date (10 April 2026).
Brivaracetam is approved internationally under the brand name Briviact® (UCB Pharma):
- USA (FDA): Approved as adjunctive therapy and monotherapy for focal onset seizures in patients aged ≥ 1 month
- EU (EMA): Approved as adjunctive therapy for focal onset seizures in adults and children aged ≥ 2 years
- Available formulations: Oral tablets (10, 25, 50, 75, 100 mg), oral solution (10 mg/mL), and intravenous solution (10 mg/mL)
Healthcare professionals seeking prescribing information should refer to the FDA or EMA-approved Product Information (PI) for Briviact® until a TGA registration application is lodged and approved.
Safety Considerations
Please refer to the FDA or EMA-approved Product Information (PI) for Briviact® for comprehensive safety information, including warnings and precautions, contraindications, and drug-drug interactions. No TGA-approved PI is currently available in Australia. Key areas to review in the international PI include psychiatric adverse events (irritability, aggression — which appear to occur at lower rates than with levetiracetam), somnolence, dizziness, and teratogenicity considerations in women of childbearing potential.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trials have directly evaluated Brivaracetam specifically in visual epilepsy, and while the mechanistic link via SV2A-mediated suppression of occipital cortical hyperexcitability is biologically plausible and indirectly supported by the Photoparoxysmal Response (PPR) model, the available published literature relates to general focal-onset epilepsy rather than the specific visual epilepsy indication. The drug’s absence from the Australian market (0 ARTG entries) adds a further regulatory barrier that must be addressed before any clinical application in Australia.
To proceed, the following is needed:
- Dedicated clinical investigation in photosensitive and visually-triggered epilepsy using the validated PPR model or prospective observational registries
- A formal TGA registration or Special Access Scheme (SAS) / Authorised Prescriber (AP) pathway assessment for Australian use
- Formal mechanism of action documentation from DrugBank and the approved PI
- Australian-specific safety monitoring plan and pharmacovigilance framework
- Consideration that Status Epilepticus (Rank 2: TxGNN score 99.40%, 2 clinical trials including one completed head-to-head vs levetiracetam in paediatric patients, 20 publications, 2 systematic reviews, recommendation: Proceed with Guardrails) represents a more immediately actionable and evidence-supported development target — this indication merits prioritisation ahead of visual epilepsy for any near-term clinical or regulatory strategy in Australia
Disclaimer: This report is intended for research reference only and does not constitute medical advice. All drug repurposing candidates require rigorous clinical validation before therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.